The work, led by researchers including J. H. Lee, Z. Li and J. S. Soto, combines several advanced approaches to reconstruct these interactions in experimental autoimmune encephalomyelitis (EAE), a widely used mouse model of multiple sclerosis. The investigators used rabies barcode interaction detection followed by sequencing to identify which cells physically contacted one another. They paired this strategy with single-cell RNA sequencing, in vitro astrocyte–T cell co-cultures and cell-specific CRISPR–Cas9 genetic perturbations performed in vivo. Together, these methods allowed the team to distinguish merely neighboring cells from cells engaged in functional immune communication.

Astrocytes are not professional antigen-presenting cells in the same way as dendritic cells, macrophages or B cells. Under inflammatory conditions, however, they can acquire components of the antigen-presentation machinery. MHC-II molecules display peptide fragments to CD4+ T cells, while CD40 functions as a costimulatory receptor capable of amplifying inflammatory signaling. The study found that astrocytes bearing both CD40 and MHC-II are not passive bystanders in CNS autoimmunity. Instead, they can help activate and maintain T cell responses within nervous tissue, creating a local environment favorable to continued inflammation.

To examine the consequences of direct cell-to-cell contact, the researchers used SorTagging, a system designed to label immune partnerships whenever two cells interact. This enabled them to isolate and analyze CD4+ T cells that had physically contacted astrocytes during EAE. The interacting T cells displayed features associated with pathogenic T helper 17 cells, or Th17 cells. These cells produce inflammatory mediators, including interleukin-17, and are strongly implicated in the development of autoimmune damage in the CNS. Direct contact with astrocytes enhanced the Th17 response, suggesting that astrocytes may help shape the behavior of infiltrating T cells rather than simply responding to signals released by them.

The interaction also changed the astrocytes themselves. The investigators focused on CD40, which is activated when it binds CD40 ligand, or CD40L, expressed by activated CD4+ T cells. According to the study, CD40 stimulation caused astrocytes to accumulate lipid droplets containing the protein PLIN4. Lipid droplets are intracellular organelles increasingly recognized as dynamic metabolic and signaling centers, rather than inert fat stores. In this setting, the droplets appear to supply acetyl-CoA, a central metabolic intermediate that can also serve as a substrate for protein acetylation.

The researchers propose that this metabolic shift strengthens nuclear factor kappa B, or NF-κB, signaling in astrocytes. NF-κB is a major transcriptional regulator of inflammation. Acetyl-CoA generated in association with PLIN4-positive lipid droplets supports acetylation of p65, a key NF-κB subunit. Acetylated p65 can promote inflammatory gene expression and increase the cell’s capacity to present antigen. This creates a potentially self-reinforcing circuit: CD4+ T cells activate astrocytes through CD40L, activated astrocytes accumulate lipid droplets and intensify NF-κB activity, and the resulting antigen presentation further stimulates autoimmune T cells.

To investigate the molecular details of the CD40 pathway, the study combined in vivo subproteomic analyses with AlphaFold-Multimer structural predictions. Subproteomics can reveal changes in defined protein populations and their modifications in specific cellular contexts, while AlphaFold-Multimer can help predict how proteins may assemble or interact. These analyses supported a mechanistic connection between CD40 signaling, PLIN4-positive lipid droplets, acetyl-CoA availability and p65 acetylation. The findings suggest that metabolism is not merely a consequence of astrocyte activation; it may be an essential part of the mechanism that makes these cells immunologically powerful.

Genetic experiments strengthened the causal interpretation. By perturbing genes specifically in astrocytes using CRISPR–Cas9-based approaches, the researchers tested whether the identified pathway influenced disease rather than simply accompanying it. The results indicated that astrocytic CD40 and MHC-II contribute to CNS autoimmunity in EAE. Removing or disrupting components of this system reduced the ability of astrocytes to support pathogenic T cell activity, placing these cells directly within the disease mechanism. The work therefore expands the cellular map of multiple sclerosis beyond infiltrating leukocytes and emphasizes the importance of immune functions acquired by resident CNS cells.

The findings were also examined in human disease material. Single-nucleus RNA sequencing and immunohistochemistry detected astrocytes expressing CD40 and MHC-II, together with lipid-droplet-associated features, in samples from people with multiple sclerosis. Although these observations do not by themselves prove that the same pathway causes disease in patients, they provide evidence that the cellular state identified in mice is relevant to human pathology. The study points to astrocyte–T cell contact, CD40–CD40L signaling and lipid metabolism as possible therapeutic targets, while also highlighting the challenge of interrupting harmful immune activity without compromising the essential support functions of astrocytes. More broadly, the research reveals how a direct conversation between a resident brain cell and an autoimmune T cell can transform local metabolism into a driver of inflammation.

Subject of Research: Astrocyte–CD4+ T cell interactions, antigen presentation, lipid-droplet metabolism and central nervous system autoimmunity in multiple sclerosis and experimental autoimmune encephalomyelitis.

Article Title: Antigen presentation by CD40+MHC-II+ astrocytes promotes CNS autoimmunity

Article References: Lee, JH., Li, Z., Soto, J.S. et al. “Antigen presentation by CD40⁺MHC-II⁺ astrocytes promotes CNS autoimmunity.” Nature (2026). https://doi.org/10.1038/s41586-026-10860-6

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41586-026-10860-6

Keywords: Multiple sclerosis, experimental autoimmune encephalomyelitis, astrocytes, CD4+ T cells, Th17 cells, CD40, CD40L, MHC-II, antigen presentation, PLIN4, lipid droplets, acetyl-CoA, NF-κB, neuroinflammation, CRISPR–Cas9, single-cell RNA sequencing.

Multiple sclerosis, a debilitating condition characterized by immune-mediated damage to myelin sheaths enveloping neurons, has long puzzled scientists with its multifactorial etiology involving genetic predisposition and environmental triggers. Recently, the gut microenvironment has emerged as a critical player in modulating systemic immune responses, but the precise cellular mechanisms bridging the gut and CNS inflammation remained elusive. The report from Dr. Shohei Suzuki and Dr. Tomohisa Sujino’s team offers groundbreaking evidence positioning the gut mucosal immune system at the epicenter of MS pathogenesis.

The investigation began by examining the gut milieu in both experimental autoimmune encephalomyelitis (EAE) mouse models and human MS patients. Single-cell RNA sequencing of intestinal biopsies revealed an accumulation of inflammatory Th17 cells in the ileum, a segment of the small intestine, highlighting a conserved immunological signature across species. This observation prompted further exploration into the antigen-presenting properties of intestinal epithelial cells, previously not considered pivotal in immune activation under homeostatic conditions.

Remarkably, IECs from both EAE mice and MS patients exhibited upregulated expression of major histocompatibility complex class II (MHC II) molecules. These molecules are traditionally expressed by professional antigen-presenting cells such as dendritic cells and macrophages, not by epithelial cells. Functional assays showed that IECs could directly present antigens to naïve CD4+ T cells in an MHC II-dependent manner and drive their differentiation into pro-inflammatory Th17 cells. This finding fundamentally shifts the paradigm of gut epithelial cells as passive barriers to active immunological hubs capable of shaping T cell responses.

To establish the causal role of IEC-mediated antigen presentation in disease progression, the researchers employed genetically engineered mice lacking MHC II expression specifically in IECs. These mice showed significantly diminished generation of pathogenic Th17 cells and a corresponding reduction in EAE severity, underscoring the impact of IECs in neuroinflammation. Thus, MHC II expression by intestinal epithelia emerges as a pivotal factor in the initiation and amplification of CNS autoimmune responses.

Central to understanding the fate of these gut-primed Th17 cells was the use of the Kaede photoconvertible protein model, which allows precise tracking of immune cells from the gut to the CNS. Upon exposure to violet light, Kaede undergoes a fluorescence shift, enabling researchers to trace the migration patterns of intestinally induced Th17 cells. This elegant approach demonstrated that these encephalitogenic cells infiltrate the spinal cord, directly contributing to neuroinflammation in EAE mice.

The implications of these discoveries are profound. They suggest that the gut is not only a site of microbial sensing but also a critical immune-educating environment where IECs actively instruct T cells toward pathogenicity. This contradicts prior dogma minimizing the role of epithelial cells in adaptive immunity and highlights the need to rethink therapeutic strategies targeting early immune events in the gut to mitigate CNS autoimmunity.

Current therapeutic regimens for MS primarily focus on inhibiting B cells or systemic immunosuppression, which often come with significant side effects and limited efficacy in halting disease progression. The identification of the gut epithelium as a nexus for pathogenic T cell induction opens potential for novel interventions that modulate gut immune functions or microbial interactions to curb autoimmune responses at their source.

Moreover, this research enriches the broader understanding of the gut-brain axis and its role in other neurodegenerative conditions such as Parkinson’s and Alzheimer’s diseases. By delineating cellular events that initiate neuroinflammatory cascades, the study bridges immunology, neurology, and microbiology, exemplifying the power of interdisciplinary approaches in addressing complex diseases.

The molecular mechanisms by which IECs upregulate MHC II in response to neuroinflammatory cues remain a topic of active investigation. The interplay between microbial metabolites, cytokine signaling, and epithelial gene expression forms a sophisticated network that modulates immune cell priming. Dissecting these pathways holds promise for identifying molecular targets amenable to pharmacological manipulation.

Future studies are anticipated to explore how gut microbiota composition influences IEC antigen-presentation dynamics and Th17 cell polarization, potentially paving the way for microbiota-based therapies. Probiotic, prebiotic, or dietary interventions tailored to reshape the intestinal microenvironment may become part of integrated treatment paradigms for MS and related autoimmune conditions.

The scientific community is watching closely as these findings represent a paradigm shift, transforming our conception of autoimmune neuroinflammation. By unmasking the gut epithelium as a key driver of pathogenic CD4+ T cell responses, this research sets the stage for therapeutics that could drastically improve patient outcomes and quality of life for those afflicted with MS.

In summary, the study from Keio University unravels a vital mechanistic link between intestinal epithelial antigen presentation and the generation of encephalitogenic Th17 cells, establishing the gut as a critical arena for autoimmune CNS disease initiation. This discovery advances our understanding of MS pathogenesis and heralds novel gut-targeted therapeutic strategies that may one day revolutionize treatment for debilitating neurological disorders.

Subject of Research: Animals
Article Title: Intestinal epithelial MHC class II induces encephalitogenic CD4⁺ T cells and initiates central nerves system autoimmunity
News Publication Date: 27-Mar-2026
References: DOI: 10.1126/sciimmunol.aec1627
Image Credits: Associate Professor Tomohisa Sujino, Keio University, Japan